Open label extension to R076477-SCH-305 to evaluate the safety and tolerability of paliperidone ER [extended release] in subjects with schizophrenia
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2010
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 31 Mar 2010 Actual patient number (407) added as reported by ClinicalTrials.gov.
- 23 May 2008 New trial record.